Since the outbreak of COVID-19, Hadassah Hospital is in a key position at the forefront of patient care, research & development, of innovative drug trials finding effective treatment.
Hadassah Hospital in Jerusalem is responding to multiple unprecedented challenges, all at once. Currently the Covid-19 pandemic in Israel represents a serious emergency with 164% Intensive Care occupancy for our hospitals.
As Israel and the world learn to live through the pandemic era, Hadassah continues to develop and expand its ongoing activity as a centre of excellence in both research and treatment. Our researchers continue to impress the world with discoveries of novel solutions both to COVID-19 and other diseases and share these around our globe. Hadassah’s success in research is down to our approach of “translational” medicine, in which Hadassah excels. This is an interdisciplinary method that takes research in the laboratory straight back to the patient-quickly!
Hadassah’s medical experts are “spreading the word from Jerusalem”. Sharing this advanced applied research from Hadassah with a worldwide network of hospitals and communities including the UK, to extend our help and assistance in the fight against Coronavirus.
Today’s Research is Tomorrow’s Care – Hadassah is leading the way in finding and sharing potential treatments quickly:
- Hadassah is the first hospital in Israel to offer outpatient treatment to vulnerable COVID-19 patients to prevent the progression of their disease and the need for hospitalisation. The treatment planned for these patients is the one-time antibody therapy called Bamlanivimab, intended for use in the beginning stages of the illness after the patient has tested positive for COVID-19 on a PCR test.
- Early trials of Allocetra™, an experimental drug developed by Prof. Dror Mevorach, head of one of the COVID-19 units at Hadassah have shown great success in treating seriously ill COVID-19 patients. In the phase one and two trials, the drug had a 90 percent recovery rate. According to Prof. Mevorach, the chief scientific and medical officer at Enlivex, the maker of the drug, “it is useful for serious and critical patients because it can prevent the need to ventilate them, and that’s the major goal. Because the moment you go into ventilation, the entire situation changes, complications rise, and it’s more difficult to treat.” In phase three trials beginning now, the drug will be administered to more than 100 patients.
- Hadassah opens Israel’s first Paediatric Covid-19 Clinic dedicated to treating Coronavirus in infants.
- Hadassah, the Israel Institute for Biological Research, and Tera Novel, an Israeli start-up company, have collaboratively developed an innovative antiviral and antibacterial mask, which contains a disinfectant that has been proven to be 99.99 percent effective in killing the coronavirus.
- In response to the large number of COVID-19 patients suffering from lingering health issues long after they recover from the virus, Hadassah has opened a multidisciplinary clinic at its Pulmonary Institute to monitor and assess their physical and psychological symptoms.
- Phase I of the first clinical trial with Brilife, the COVID-19 vaccine developed by the Israel Institute for Biological Research, was completed at Hadassah Hospital Ein Kerem on November 26, when the 40th participant received the final dose. Prof. Yossi Karko, director of the centre, explained the success to date: “From monitoring the participants who have been vaccinated so far, we see no unusual side effects, and this seems promising in terms of safety, which is the point of the first stage of the experiment. We can now look forward to the next stage.”
- The newly established Wohl Centre for Translational Medicine at Hadassah, builds on the extensive R&D infrastructure to improve scientific knowledge about drugs, diseases and their pathways, finding ways to apply this knowledge in a clinical setting to benefit patient care.
- Hadassah participated in a World Health Organisation (WHO) trial with the drug Remdesivir. Other medicines are being tested to stop the formation of the virus, while others block the virus from penetrating to the body’s cells.
- Hadassah researchers and SodaStream engineers unveiled a jointly developed innovative respiratory device creating high-flow oxygen systems to treat COVID-19 that help address the critical need for respirators in hospitals and healthcare facilities.
- Hadassah’s clinical trial enrich COVID-19-specific “T” cells of the immune system from recovered patients to treat patients who are severely ill with the virus. Plasma collected from recovered COVID-19 patients is also used for treatment.
- Hadassah is studying blood samples of COVID-19 to identify biomarkers that make people more susceptible or resistant to the disease.
- More than 30% of COVID-19 patients suffer from blood clots creating lethal blockages in the lungs, kidneys, heart and brain. Hadassah has found the mechanism that causes them. They are now working on a new way to dissolve these blood clots. Hadassah believes if the drug works to reduce blood clots in COVID-19, it will vastly reduce the numbers of patients needing respirators.
Thanks to the generosity of our donors, our Hospital has been able to cope with Israel’s most acute cases of the Coronavirus at the quickly established COVID-19 Units at Hadassah. Our current infrastructure continues to be critical for Jerusalem and Israel today.
With your help we can ensure that our medical teams have the essential equipment to treat, research and share this information globally including the UK.
With support from our valued donors, we are already saving lives and infra structure around the world to help mitigate the impact of Covid-19